Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28762468 | 0.86 | POLB (0.41) | POLBCFTRTDP1KDM4EL3MBTL1 | |
| SCHEMBL20745291 | 0.81 | HSD17B10 (0.40) | POLBCFTRTDP1KDM4EL3MBTL1 | |
| SCHEMBL23616411 | 0.79 | HSD17B10 (0.41) | POLBTDP1KDM4EL3MBTL1PIN1 | |
| SCHEMBL2372350 | 0.78 | CFTR (0.60) | CFTR | |
| SCHEMBL22791078 | 0.76 | CFTR (0.53) | POLBCFTRTDP1 | |
| SCHEMBL22791248 | 0.76 | POLB (0.36) | POLBTDP1KDM4EL3MBTL1PIN1 | |
| SCHEMBL23538046 | 0.75 | CFTR (0.42) | CFTRTDP1KDM4EGABRPGABRD | |
| SCHEMBL1674658 | 0.74 | PIK3CA (0.37) | POLBALDH1A1 | |
| SCHEMBL21372397 | 0.74 | CYP3A4 (0.37) | POLBKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL31345511 | 0.74 | PIK3CA (0.37) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2020-12-10 | — | — | US | disclosed |
| US-10633341-B2 | Picolinic acid derivatives and their use as intermediates | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| US-20190345107-A1 | NEW PICOLINIC ACID DERIVATIVES AND THEIR USE AS INTERMEDIATES | NOVARTIS AG (CH) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | POLB 2724/4885CFTR 1/4885TDP1 3600/4885 |
| US-20190345107-A1 | NEW PICOLINIC ACID DERIVATIVES AND THEIR USE AS INTERMEDIATES | PYCR1, HADHA, HPD | POLB 2521/4885CFTR 649/4885TDP1 4374/4885 |
| US-10633341-B2 | Picolinic acid derivatives and their use as intermediates | HPD, PYCR1, PAH | POLB 2715/4885CFTR 946/4885TDP1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.